Extendicare Inc. (TSE:EXE – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$18.31 and traded as high as C$24.88. Extendicare shares last traded at C$24.55, with a volume of 1,167,487 shares trading hands.
Analysts Set New Price Targets
EXE has been the subject of a number of recent analyst reports. Cormark raised their price objective on Extendicare from C$25.00 to C$30.00 in a research report on Wednesday, December 3rd. Canadian Imperial Bank of Commerce lifted their price target on shares of Extendicare from C$18.00 to C$22.00 in a research report on Thursday, November 13th. Royal Bank Of Canada raised shares of Extendicare from a “hold” rating to a “moderate buy” rating and boosted their price target for the company from C$15.00 to C$25.00 in a research note on Thursday, December 4th. National Bank Financial increased their price objective on shares of Extendicare from C$24.50 to C$29.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Finally, TD Securities lifted their target price on shares of Extendicare from C$15.00 to C$19.00 in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of C$24.50.
Read Our Latest Stock Analysis on EXE
Extendicare Price Performance
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
